Cargando…

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

BACKGROUND: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be a potential anti-fibrotic drug to improve the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinas, E., Luburich-Hernaiz, P., Dorca, J., Montes-Worboys, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922028/ https://www.ncbi.nlm.nih.gov/pubmed/29703175 http://dx.doi.org/10.1186/s12890-018-0626-4

Ejemplares similares

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2016)

Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1
por: Estany, Susanna, et al.
Publicado: (2014)

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2018)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
por: Bordas-Martinez, Jaume, et al.
Publicado: (2021)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Pirfenidone improves survival in IPF: results from a real-life study
por: Margaritopoulos, George A., et al.
Publicado: (2018)

Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells
por: Merino, Ana, et al.
Publicado: (2021)

A prospective study of lung disease in a cohort of early rheumatoid arthritis patients
por: Robles-Pérez, A., et al.
Publicado: (2020)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction
por: Planas-Cerezales, Lurdes, et al.
Publicado: (2021)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts
por: Machahua, Carlos, et al.
Publicado: (2021)

Short telomere length in IPF lung associates with fibrotic lesions and predicts survival
por: Snetselaar, Reinier, et al.
Publicado: (2017)

Urine-derived exosomes from individuals with IPF carry pro-fibrotic cargo
por: Elliot, Sharon, et al.
Publicado: (2022)

Diffuse alveolar hemorrhage complicating acute exacerbation of IPF
por: Murohashi, Kota, et al.
Publicado: (2020)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
por: Kang, Jieun, et al.
Publicado: (2023)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
por: Korfei, Martina, et al.
Publicado: (2018)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF
por: Sun, Jian, et al.
Publicado: (2022)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing
por: Blokland, Kaj E. C., et al.
Publicado: (2020)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain
por: Mañá, Juan, et al.
Publicado: (2017)

Radio-Histological Correlation of Lung Features in Severe COVID-19 Through CT-Scan and Lung Ultrasound Evaluation
por: Trias-Sabrià, Pere, et al.
Publicado: (2022)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kgo0s264sm38628fib8kpi3v6r